Are you pregnant and at risk for blood clots?
PROSPER Trial (PostpaRtum PrOphylaxiS for PE Randomized Control Trial) Pilot: A Pilot Study Assessing Feasibility of a Randomized, Open-label Trial of Low-Molecular-Weight-Heparin for Postpartum Prophylaxis in Women at Risk of Developing Venous Thromboembolism
Obstetrics & Gynecology
James Andra, H
Research has shown that some women are at an increased risk of developing blood clots after delivering their babies. Blood clots are the leading cause of death in pregnancy and after delivery. The purpose of the PROSPER Trial (PostpaRtum PrOphylaxiS for PE Randomized Control Trial) is to see if a low dose blood thinner called low-molecular-weight-heparin (LMWH) can safely reduce the risk of developing blood clots in postpartum woman at risk. You may qualify for the study if you have the following risks for blood clots: • You have been on bed rest during your pregnancy • OR you have low risk Thrombophilia (blood clotting tendency) You may also qualify if you: • Have pre-eclampsia (high blood pressure and protein in your urine) during this pregnancy • Have an emergency caesarean section (with this baby) • Lose a lot of blood during delivery (or right after birth of this baby) • Have an infection after giving birth • Smoke (prior to or during pregnancy) • Were overweight before getting pregnant • Give birth to a very small birth weight baby Study-related tests and experimental medication provided free of charge. Compensation for study completion is $60.00 Contact Information: If you are interested in learning more about the PROSPER Trial, please call: • Katie L. Sullivan, MSW, CCRC • 434-924-1311, email@example.com • Insert IRB-HSR # 16514 Principal Investigator: Andra James, MD, MPH
Postpartum (after delivery)
Compensation for study completion is $60.00